Promising Potential of VYNE Therapeutics’ Repibresib Gel in Phase IIb Study

Analyst Rami Katkhuda from LifeSci Capital maintained a Buy rating on VYNE Therapeutics and keeping the price target at $6.00.

Rami Katkhuda’s rating is based on the promising potential of VYNE Therapeutics’ repibresib gel, which is currently undergoing a Phase IIb study. The study is testing higher concentrations of the gel, which could enhance its efficacy while maintaining a favorable safety profile. The ongoing trial is also extending the evaluation period to 24 weeks and includes both active and stable disease subjects, potentially offering a competitive edge over existing JAK inhibitors.
Katkhuda believes that if repibresib demonstrates efficacy comparable to Incyte’s Opzelura by the 24-week mark, it could significantly boost VYNE’s stock value. Additionally, the once-daily administration and anticipated absence of a black box warning make repibresib an attractive first-line treatment option in the expanding nonsegmental vitiligo market, provided its clinical benefits are on par with current therapies.

In another report released on July 3, H.C. Wainwright also reiterated a Buy rating on the stock with a $4.50 price target.